Tema Heart & Health ETF HRTS
39.75 USD +1.09 (+2.82%)
Nov 4, 2026, 1:11 PM EST
39.45 Day range 39.74
32.27 52-week range 39.74
- YTD
- +12.64%
- 1 year
- +22.69%
- Market cap
- 57.18M
- EPS (ttm)
- 1.37
- P/E ratio
- 28.90
- YTD return
- +12.64%
- 1-year return
- +22.69%
- Volume
- 1.00K
- Avg volume
- 2.21K
- Open
- 39.45
- Previous close
- 38.66
- Day's range
- 39.45 – 39.74
- 52-week range
- 32.27 – 39.74
1Y +6.89 (+21.12%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 32.41
- 200-day average
- 33.09
About Tema Heart & Health ETF
Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from products or services related to GLP-1 and the treatment of cardiovascular diseases and/or metabolic diseases, as defined by the Centers for Diseases Control and Preventions. The fund generally is expected to consist of more than 15 companies but not more than 100 companies. The fund is non-diversified.
News
Obesity ETFs to Gain as Novo's CagriSema Shows 25% Weight Loss 
Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win 
Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage 
Tema ETFs Exceeds $5bn in AUM After Three Years 
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market 
From Shingles To Superbugs: Eli Lilly Expands Infectious Disease Push In Billion-Dollar Buying Wave 
GLP-1 Drug Giants Race to Go Global With Their Obesity Pills: ETFs to Gain 
Tema ETFs Surpasses $2 Billion in AUM in Under Three Years 
Why Is Eli Lilly Stock Gaining Today? 
'Roche Restricts Consulting Work With Big Four Firms To Cut Costs' - Bloomberg
Your note
Sign in to keep a note on HRTS — it syncs with the Stock Master app.